Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats

Significance Using structure-based drug design, we have identified a series of potent allosteric protein–protein interaction acetyl-CoA carboxylase inhibitors, exemplified by ND-630, that interact within the acetyl-CoA carboxylase subunit phosphopeptide acceptor and dimerization site to prevent dimerization and inhibit enzymatic activity. ND-630 reduces fatty acid synthesis and stimulates fatty acid oxidation in cultured cells and experimental animals, reduces hepatic steatosis, improves insulin sensitivity, reduces weight gain without affecting food intake, and favorably affects dyslipidemia in diet-induced obese rats and reduces hepatic steatosis, improves glucose-stimulated insulin secretion, and reduces hemoglobin A1c in Zucker diabetic fatty rats. These data suggest that ND-630 may be useful in treating a variety of metabolic disorders, including metabolic syndrome, type 2 diabetes, and fatty liver disease. Simultaneous inhibition of the acetyl-CoA carboxylase (ACC) isozymes ACC1 and ACC2 results in concomitant inhibition of fatty acid synthesis and stimulation of fatty acid oxidation and may favorably affect the morbidity and mortality associated with obesity, diabetes, and fatty liver disease. Using structure-based drug design, we have identified a series of potent allosteric protein–protein interaction inhibitors, exemplified by ND-630, that interact within the ACC phosphopeptide acceptor and dimerization site to prevent dimerization and inhibit the enzymatic activity of both ACC isozymes, reduce fatty acid synthesis and stimulate fatty acid oxidation in cultured cells and in animals, and exhibit favorable drug-like properties. When administered chronically to rats with diet-induced obesity, ND-630 reduces hepatic steatosis, improves insulin sensitivity, reduces weight gain without affecting food intake, and favorably affects dyslipidemia. When administered chronically to Zucker diabetic fatty rats, ND-630 reduces hepatic steatosis, improves glucose-stimulated insulin secretion, and reduces hemoglobin A1c (0.9% reduction). Together, these data suggest that ACC inhibition by representatives of this series may be useful in treating a variety of metabolic disorders, including metabolic syndrome, type 2 diabetes mellitus, and fatty liver disease.

[1]  S. Grzesiek,et al.  NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.

[2]  Liang Tong,et al.  Crystal Structure of the Carboxyltransferase Domain of Acetyl-Coenzyme A Carboxylase , 2003, Science.

[3]  D. Hargrove,et al.  Isozyme-nonselective N-Substituted Bipiperidylcarboxamide Acetyl-CoA Carboxylase Inhibitors Reduce Tissue Malonyl-CoA Concentrations, Inhibit Fatty Acid Synthesis, and Increase Fatty Acid Oxidation in Cultured Cells and in Experimental Animals* , 2003, Journal of Biological Chemistry.

[4]  L. Olson,et al.  Soraphen A, an inhibitor of acetyl CoA carboxylase activity, interferes with fatty acid elongation. , 2011, Biochemical pharmacology.

[5]  S. Chirala,et al.  The subcellular localization of acetyl-CoA carboxylase 2. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Randy J Read,et al.  Electronic Reprint Biological Crystallography Phenix: Building New Software for Automated Crystallographic Structure Determination Biological Crystallography Phenix: Building New Software for Automated Crystallographic Structure Determination , 2022 .

[7]  L. Tong,et al.  Crystal structure of the 500 kD yeast acetyl-CoA carboxylase holoenzyme dimer , 2015, Nature.

[8]  K. Kim,et al.  Identification of a second human acetyl-CoA carboxylase gene. , 1996, The Biochemical journal.

[9]  S. Wakil,et al.  Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  H. Harwood,et al.  The adipocyte as an endocrine organ in the regulation of metabolic homeostasis , 2012, Neuropharmacology.

[11]  G. Etgen,et al.  Profiling of Zucker diabetic fatty rats in their progression to the overt diabetic state. , 2000, Metabolism: clinical and experimental.

[12]  T. Watts,et al.  Identification of an isozymic form of acetyl-CoA carboxylase. , 1990, The Journal of biological chemistry.

[13]  B. Berne,et al.  Role of the active-site solvent in the thermodynamics of factor Xa ligand binding. , 2008, Journal of the American Chemical Society.

[14]  G. Shulman,et al.  Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. , 2006, The Journal of clinical investigation.

[15]  Liang Tong,et al.  Acetyl‐coenzyme A carboxylases: Versatile targets for drug discovery , 2006, Journal of cellular biochemistry.

[16]  D. James,et al.  Acute or chronic upregulation of mitochondrial fatty acid oxidation has no net effect on whole-body energy expenditure or adiposity. , 2010, Cell metabolism.

[17]  Liang Tong,et al.  Molecular basis for the inhibition of the carboxyltransferase domain of acetyl-coenzyme-A carboxylase by haloxyfop and diclofop. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[19]  R. Synovec,et al.  Cardiac-Specific Deletion of Acetyl CoA Carboxylase 2 Prevents Metabolic Remodeling During Pressure-Overload Hypertrophy , 2012, Circulation research.

[20]  R. Brownsey,et al.  Regulation of acetyl-CoA carboxylase. , 2006, Biochemical Society transactions.

[21]  E. Ravussin,et al.  Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes , 2014, Journal of medicinal chemistry.

[22]  N. Ruderman,et al.  Lipid abnormalities in tissues of the KKAy mouse: effects of pioglitazone on malonyl-CoA and diacylglycerol. , 1994, The American journal of physiology.

[23]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[24]  L. Tong,et al.  Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and attractive target for drug discovery , 2005, Cellular and Molecular Life Sciences CMLS.

[25]  R. McPherson,et al.  Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2. , 2010, Bioorganic & medicinal chemistry letters.

[26]  Martin M. Matzuk,et al.  Continuous Fatty Acid Oxidation and Reduced Fat Storage in Mice Lacking Acetyl-CoA Carboxylase 2 , 2001, Science.

[27]  J. Yates,et al.  TRB3 Links the E3 Ubiquitin Ligase COP1 to Lipid Metabolism , 2006, Science.

[28]  M. P. Bourbeau,et al.  Recent advances in the development of acetyl-CoA carboxylase (ACC) inhibitors for the treatment of metabolic disease. , 2015, Journal of medicinal chemistry.

[29]  P. Nordlund,et al.  Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination , 2006, Proceedings of the National Academy of Sciences.

[30]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[31]  K. Kim,et al.  Regulation of mammalian acetyl-coenzyme A carboxylase. , 1997, Annual review of nutrition.

[32]  Liang Tong,et al.  A mechanism for the potent inhibition of eukaryotic acetyl-coenzyme A carboxylase by soraphen A, a macrocyclic polyketide natural product. , 2004, Molecular cell.

[33]  L. Tong,et al.  Structure and function of biotin-dependent carboxylases , 2012, Cellular and Molecular Life Sciences.

[34]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[35]  Moshe Levi,et al.  Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. , 2011, Circulation.

[36]  B. Wang,et al.  Synthesis and characterization of a BODIPY-labeled derivative of Soraphen A that binds to acetyl-CoA carboxylase. , 2009, Bioorganic & medicinal chemistry letters.

[37]  G. Chang,et al.  CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. , 2003, Journal of lipid research.

[38]  L. Tong,et al.  Crystal structure of the carboxyltransferase domain of acetyl-coenzyme A carboxylase in complex with CP-640186. , 2004, Structure.

[39]  D. Stiller,et al.  Inhibition of acetyl-CoA carboxylase 2 enhances skeletal muscle fatty acid oxidation and improves whole-body glucose homeostasis in db/db mice , 2012, Diabetologia.

[40]  Jeremy R. Greenwood,et al.  Epik: a software program for pKa prediction and protonation state generation for drug-like molecules , 2007, J. Comput. Aided Mol. Des..

[41]  A. Mattiello-Sverzut,et al.  Characterization of Fiber Types in Different Muscles of the Hindlimb in Female Weanling and Adult Wistar Rats , 2011, Acta histochemica et cytochemica.

[42]  E. Rassart,et al.  Lipogenesis in cancer progression (review). , 2014, International journal of oncology.

[43]  Thomas A. Halgren,et al.  Identifying and Characterizing Binding Sites and Assessing Druggability , 2009, J. Chem. Inf. Model..

[44]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[45]  P. O S I T I O N S T A T E M E N T,et al.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[46]  Hyun-soo Cho,et al.  Molecular mechanism for the regulation of human ACC2 through phosphorylation by AMPK. , 2010, Biochemical and biophysical research communications.

[47]  J. McGarry,et al.  The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. , 1997, European journal of biochemistry.

[48]  H. Taegtmeyer,et al.  Decreased long‐chain fatty acid oxidation impairs postischemic recovery of the insulin‐resistant rat heart , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[49]  J. Dyck,et al.  Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin–sensitizing effects of metformin , 2013, Nature Medicine.

[50]  B. Lowell,et al.  Gene knockout of Acc2 has little effect on body weight, fat mass, or food intake , 2010, Proceedings of the National Academy of Sciences.

[51]  H. J. Harwood,et al.  Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition. , 2005, Expert opinion on therapeutic targets.

[52]  K. Ohbuchi,et al.  Hepatic De Novo Lipogenesis Is Present in Liver-Specific ACC1-Deficient Mice , 2007, Molecular and Cellular Biology.

[53]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[54]  R. Harris,et al.  Mechanism responsible for 5-(tetradecyloxy)-2-furoic acid inhibition of hepatic lipogenesis. , 1979, The Journal of biological chemistry.

[55]  J. Ontko,et al.  Interactions between fatty acid synthesis, oxidation, and esterification in the production of triglyceride-rich lipoproteins by the liver. , 1984, Journal of lipid research.

[56]  B. Neuschwander‐Tetri.  Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites , 2010, Hepatology.